The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Blood

• Publication date

  2007-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD-2006-04-015230PMID 17327417
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation.

  2007cited by this paper
• Suicide is painless

  2006cited by this paper
• Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.

  2006cited by this paper
• HSV-TK Engineered Donor Lymphocytes Add-Backs Reduce Late Mortality and Improve Survival of High Risk Acute Leukemia after Haplo-HSCT: Results of a Phase II Multicenter Trial.

  2005cited by this paper
• An inducible caspase 9 safety switch for T-cell therapy.

  2005cited by this paper
• MHC ligands and peptide motifs: first listing

  2004cited by this paper
• Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells.

  2004cited by this paper
• Human Immune Responses to AAV-2 Capsid May Limit Duration of Expression in Liver-Directed Gene Transfer in Humans with Hemophilia B.

  2004cited by this paper
• Genetic modification of T lymphocytes for adoptive immunotherapy.

  2004cited by this paper
• Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial.

  2003cited by this paper
• Safety of retroviral gene marking with a truncated NGF receptor

  2003cited by this paper
• A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease.

  2001cited by this paper
• In Vivo Persistence of Retrovirally Transduced Murine Long-Term Repopulating Cells Is Not Limited by Expression of Foreign Gene Products in the Fully or Minimally Myeloablated Setting

  2001cited by this paper
• Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells.

  2001cited by this paper
• Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model.

  2000cited by this paper
• Genetic Modification of Human T Cells with CD20: A Strategy to Purify and Lyse Transduced Cells with Anti-CD20 Antibodies

  2000cited by this paper
• Therapeutic vaccination for cancer.

  2000cited by this paper
• Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency.

  1999cited by this paper
• Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11

  1999cited by this paper
• Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family.

  1999cited by this paper
• Herpes Simplex Virus Thymidine Kinase Gene Transfer for Controlled Graft-versus-Host Disease and Graft-versus-Leukemia: Clinical Follow-up and Improved New Vectors

  1998cited by this paper
• Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

  1998cited by this paper
• Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells

  1997cited by this paper
• HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.

  1997influential reference
• The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.

  1996cited by this paper
• T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients

  1996cited by this paper
• Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes

  1996cited by this paper
• Bcl-XL displays restricted distribution during T cell development and inhibits multiple forms of apoptosis but not clonal deletion in transgenic mice

  1995cited by this paper
• Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro.

  1995cited by this paper
• Induction in vitro of a primary human antiviral cytotoxic T cell response

  1995cited by this paper
• Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer.

  1994cited by this paper
• Transfer of the ADA Gene into Bone Marrow Cells and Peripheral Blood Lymphocytes for the Treatment of Patients Affected by ADA-Deficient SCID

  1993cited by this paper
• Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors.

  1990cited by this paper

• Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).

  2025cites this paper
• Hypoimmunogenic pluripotent stem cells: A game-changer in cell-based regenerative medicine.

  2025cites this paper
• Novel strategies to manage CAR-T cell toxicity

  2025cites this paper
• Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection

  2025cites this paper
• Facts and hopes for PET imaging-derived immunotherapy biomarkers.

  2024cites this paper
• Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation

  2024cites this paper
• Recent developments in translational imaging of in vivo gene therapy outcomes.

  2024cites this paper
• Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection

  2024cites this paper
• CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy

  2023cites this paper
• Education and Empowering Special Forces to Eradicate Secret Defectors: Immune System-Based Treatment Approaches for Mature T- and NK-Cell Malignancies

  2023cites this paper
• Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer.

  2023cites this paper
• Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a “Trojan Horse”

  2023cites this paper
• Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

  2023cites this paper
• Harnessing the Potential of Chimeric Antigen Receptor T-Cell Therapy for the Treatment of T-Cell Malignancies: A Dare or Double Dare?

  2022cites this paper
• Inducible caspase-9 suicide gene under control of endogenous oct4 to safeguard mouse and human pluripotent stem cell therapy

  2022cites this paper
• Safety Switches Used for Cellular Therapies

  2022cites this paper
• The Role of γδ T Cells as a Line of Defense in Viral Infections after Allogeneic Stem Cell Transplantation: Opportunities and Challenges

  2022cites this paper
• Strategies to overcome the side effects of chimeric antigen receptor T cell therapy

  2022cites this paper
• Engineering stem cells for cancer immunotherapy.

  2021cites this paper
• Efficient Genetic Safety Switches for Future Application of iPSC-Derived Cell Transplants

  2021cites this paper
• CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?

  2021cites this paper
• CAR-T cell persistence in the treatment of leukemia and lymphoma

  2021cites this paper
• Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells

  2021cites this paper
• Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy

  2021cites this paper
• Molecular-Targeted Imaging

  2021cites this paper
• Prodrugs and prodrug-activated systems in gene therapy

  2021cites this paper
• T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy

  2021cites this paper
• Protein Engineering for Molecular Imaging

  2021cites this paper
• Strategies for Dodging the Obstacles in CAR T Cell Therapy

  2021cites this paper
• Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity

  2021cites this paper
• PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors

  2020cites this paper
• Imaging CAR T Cell Trafficking with eDFHR as a PET Reporter Gene.

  2020cites this paper
• Metabolic engineering generates a transgene-free safety switch for cell therapy

  2020cites this paper
• Thermal Control of Engineered T-cells.

  2020cites this paper
• 18F-FHBG PET-CT Reporter Gene Imaging of Adoptive CIK Cell Transfer Immunotherapy for Breast Cancer in a Mouse Model

  2020cites this paper
• The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview

  2020cites this paper
• TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals

  2020cites this paper
• Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy

  2020cites this paper
• Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards

  2020cites this paper
• Thermal Control of T-cell Immunotherapy

  2020cites this paper
• Understanding Gamma Delta T Cell Multifunctionality - Towards Immunotherapeutic Applications

  2020cites this paper
• OTT_A_271657 11659..11668

  2020cites this paper
• Metabolic engineering generates a transgene-free safety switch for cell therapy

  2020cites this paper
• Engineered miniature H1 promoters with dedicated RNA polymerase II or III activity

  2020cites this paper
• Engineering Next-Generation CAR-T Cells for Better Toxicity Management

  2020cites this paper
• Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors

  2020cites this paper
• Genetically Engineered T Cell Therapies and Immune System Engagers for Graft-Versus-Host Disease and Graft Versus Leukemia

  2019cites this paper
• Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics

  2019cites this paper
• Rapid Regulation of Human Mesenchymal Stem Cell Proliferation Using Inducible Caspase-9 Suicide Gene for Safe Cell-Based Therapy

  2019cites this paper
• Adoptive T Cell Therapy Following Haploidentical Hematopoietic Stem Cell Transplantation

  2019cites this paper
• GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR

  2018cites this paper
• Haploidentical Transplants: Immune Reconstitution With and Without Augmentation Strategies

  2018cites this paper
• A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies

  2018cites this paper
• Molecular Approaches to Safe and Controlled Engineered T-cell Therapy

  2018cites this paper
• Fail-Safe System against Potential Tumorigenicity after Transplantation of iPSC Derivatives

  2017cites this paper
• PET Imaging in Immunology

  2017cites this paper
• Exploiting Cell Death Pathways for Inducible Cell Elimination to Modulate Graft-versus-Host-Disease

  2017cites this paper
• Quantitative PET Reporter Gene Imaging with [11C]Trimethoprim.

  2017cites this paper
• CAR T-cell therapy: Balance of efficacy and safety

  2017cites this paper
• CAR T-cells for cancer therapy

  2017cites this paper
• CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside

  2016cites this paper
• Conditional control of suicide gene expression in tumor cells with theophylline-responsive ribozyme

  2016cites this paper
• Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch.

  2016cites this paper
• Elimination of proliferating cells from CNS grafts using a Ki67 promoter-driven thymidine kinase

  2016cites this paper
• Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy

  2016cites this paper
• Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts

  2016cites this paper
• Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world

  2016cites this paper
• Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas

  2016influential citation
• Advances in PET Detection of the Antitumor T Cell Response.

  2016cites this paper
• Strategies to accelerate immune recovery after allogeneic hematopoietic stem cell transplantation

  2016cites this paper
• Biology of the Human Graft‐versus‐Tumor Response and How to Exploit It

  2016cites this paper
• HematopoieticCellTransplantation for Myelodysplastic Syndromes

  2016cites this paper
• T Cells as Antigen Carriers for Anti-tumor Vaccination.

  2016cites this paper
• Improving the safety of T-Cell therapies using an inducible caspase-9 gene.

  2016cites this paper
• Enzyme/Prodrug Systems for Cancer Gene Therapy

  2016cites this paper
• 嵌合抗原受体修饰的T细胞治疗肿瘤的不良反应及相关治疗方案的研究进展

  2016cites this paper
• Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography

  2016cites this paper
• Genetic Modification of T Cells

  2016cites this paper
• Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy

  2016cites this paper
• Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGVHD

  2016cites this paper
• Hematopoietic Cell Transplantation for Myelodysplastic Syndromes.

  2016cites this paper
• Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-TK transduced T-cells

  2015cites this paper
• Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy

  2015cites this paper
• A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy

  2015cites this paper
• Adoptive T‐cell therapy for cancer: The era of engineered T cells

  2015cites this paper
• Preventing stem cell transplantation-associated viral infections using T-cell therapy.

  2015cites this paper
• Seatbelts in CAR therapy: How Safe Are CARS?

  2015cites this paper
• Donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene: detailed immunological function following add-back after haplo-identical transplantation.

  2015cites this paper
• CAR T‐cell immunotherapy: The path from the by‐road to the freeway?

  2015cites this paper
• T Cell Immunotherapy for Immune Reconstitution and GVHD Prevention After Allogeneic Hematopoietic Stem Cell Transplantation

  2015cites this paper
• Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantation

  2015cites this paper
• Allogeneic and Autologous T cell Strategies to Enhance Targeting of Acute Myeloid Leukemias

  2015cites this paper
• CD19 chimeric antigen receptor T cell therapy for haematological malignancies

  2015cites this paper
• Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging.

  2015cites this paper
• Improving the safety of cell therapy with the TK-suicide gene

  2015cites this paper
• Control of leukemia relapse after allogeneic hematopoietic stem cell transplantation: integrating transplantation with genetically modified T cell therapies

  2015cites this paper
• Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy.

  2015cites this paper
• iCaspase 9 Suicide Gene System.

  2015cites this paper
• Synthetic biology approaches to engineer T cells.

  2015cites this paper
• Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory

  2015cites this paper